Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, Srdan Verstovsek

Research output: Contribution to journalReview article

Abstract

Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia and myelofibrosis have led to the identification of the mutation V617F in Janus kinase (JAK) as a potential therapeutic target. This information has prompted the development of ATP-competitive JAK2 inhibitors. Therapy with JAK2 inhibitors may induce rapid and marked reductions in spleen size and can lead to remarkable improvements in constitutional symptoms and overall quality of life. Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection. Preliminary results indicate that these agents hold great promise for the treatment of JAK-driven disorders.

Original languageEnglish (US)
Pages (from-to)127-140
Number of pages14
JournalNature Reviews Drug Discovery
Volume10
Issue number2
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Janus Kinases
Neoplasms
Essential Thrombocythemia
Philadelphia Chromosome
Polycythemia Vera
Primary Myelofibrosis
Immune System Diseases
Therapeutics
Psoriasis
Autoimmune Diseases
Allografts
Rheumatoid Arthritis
Spleen
Adenosine Triphosphate
Quality of Life
Clinical Trials
Mutation

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. / Quintás-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge; Verstovsek, Srdan.

In: Nature Reviews Drug Discovery, Vol. 10, No. 2, 01.02.2011, p. 127-140.

Research output: Contribution to journalReview article

Quintás-Cardama, Alfonso ; Kantarjian, Hagop ; Cortes, Jorge ; Verstovsek, Srdan. / Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. In: Nature Reviews Drug Discovery. 2011 ; Vol. 10, No. 2. pp. 127-140.
@article{34da86d72c174ba8aa7294e0ddcc19df,
title = "Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond",
abstract = "Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia and myelofibrosis have led to the identification of the mutation V617F in Janus kinase (JAK) as a potential therapeutic target. This information has prompted the development of ATP-competitive JAK2 inhibitors. Therapy with JAK2 inhibitors may induce rapid and marked reductions in spleen size and can lead to remarkable improvements in constitutional symptoms and overall quality of life. Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection. Preliminary results indicate that these agents hold great promise for the treatment of JAK-driven disorders.",
author = "Alfonso Quint{\'a}s-Cardama and Hagop Kantarjian and Jorge Cortes and Srdan Verstovsek",
year = "2011",
month = "2",
day = "1",
doi = "10.1038/nrd3264",
language = "English (US)",
volume = "10",
pages = "127--140",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Verstovsek, Srdan

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia and myelofibrosis have led to the identification of the mutation V617F in Janus kinase (JAK) as a potential therapeutic target. This information has prompted the development of ATP-competitive JAK2 inhibitors. Therapy with JAK2 inhibitors may induce rapid and marked reductions in spleen size and can lead to remarkable improvements in constitutional symptoms and overall quality of life. Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection. Preliminary results indicate that these agents hold great promise for the treatment of JAK-driven disorders.

AB - Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia and myelofibrosis have led to the identification of the mutation V617F in Janus kinase (JAK) as a potential therapeutic target. This information has prompted the development of ATP-competitive JAK2 inhibitors. Therapy with JAK2 inhibitors may induce rapid and marked reductions in spleen size and can lead to remarkable improvements in constitutional symptoms and overall quality of life. Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection. Preliminary results indicate that these agents hold great promise for the treatment of JAK-driven disorders.

UR - http://www.scopus.com/inward/record.url?scp=79551575494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551575494&partnerID=8YFLogxK

U2 - 10.1038/nrd3264

DO - 10.1038/nrd3264

M3 - Review article

C2 - 21283107

AN - SCOPUS:79551575494

VL - 10

SP - 127

EP - 140

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 2

ER -